Agosti Edoardo, Zeppieri Marco, De Maria Lucio, Mangili Marcello, Rapisarda Alessandro, Ius Tamara, Spadea Leopoldo, Salati Carlo, Tel Alessandro, Pontoriero Antonio, Pergolizzi Stefano, Angileri Filippo Flavio, Fontanella Marco Maria, Panciani Pier Paolo
Division of Neurosurgery, Department of Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25123 Brescia, Italy.
Department of Ophthalmology, University Hospital of Udine, Piazzale S. Maria Della Misericordia 15, 33100 Udine, Italy.
J Clin Med. 2023 Sep 8;12(18):5840. doi: 10.3390/jcm12185840.
Spheno-orbital meningiomas (SOMs) are rare tumors arising from the meninges surrounding the sphenoid bone and orbital structures. Surgical resection is the primary treatment approach for SOMs. Several surgical approaches have been described during the decades, including microsurgical transcranial (MTAs), endoscopic endonasal (EEAs), endoscopic transorbital (ETOAs), and combined approaches, and the choice of surgical approach remains a topic of debate.
This systematic review and meta-analysis aim to compare the clinical and surgical outcomes of different surgical approaches used for the treatment of SOMs, discussing surgical techniques, outcomes, and factors influencing surgical decision making.
A comprehensive literature review of the databases PubMed, Ovid MEDLINE, and Ovid EMBASE was conducted for articles published on the role of surgery for the treatment of SOMs until 2023. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Meta-analysis was performed to estimate pooled event rates and assess heterogeneity. Fixed- and random-effects were used to assess 95% confidential intervals (CIs) of presenting symptoms, outcomes, and complications.
A total of 59 studies comprising 1903 patients were included in the systematic review and meta-analysis. Gross total resection (GTR) rates ranged from 23.5% for ETOAs to 59.8% for MTAs. Overall recurrence rate after surgery was 20.7%. Progression-free survival (PFS) rates at 5 and 10 years were 75.5% and 49.1%, respectively. Visual acuity and proptosis improvement rates were 57.5% and 79.3%, respectively. Postoperative cranial nerve (CN) focal deficits were observed in 20.6% of cases. The overall cerebro-spinal fluid (CSF) leak rate was 3.9%, and other complications occurred in 13.9% of cases. MTAs showed the highest GTR rates (59.8%, 95%CI = 49.5-70.2%; = 0.001) but were associated with increased CN deficits (21.0%, 95%CI = 14.5-27.6%). ETOAs had the lowest GTR rates (23.5%, 95%CI = 0.0-52.5%; = 0.001), while combined ETOA and EEA had the highest CSF leak rates (20.3%, 95%CI = 0.0-46.7%; = 0.551). ETOAs were associated with better proptosis improvement (79.4%, 95%CI = 57.3-100%; = 0.002), while anatomical class I lesions were associated with better visual acuity (71.5%, 95%CI = 63.7-79.4; = 0.003) and proptosis (60.1%, 95%CI = 38.0-82.2; = 0.001) recovery. No significant differences were found in PFS rates between surgical approaches.
Surgical treatment of SOMs aims to preserve visual function and improve proptosis. Different surgical approaches offer varying rates of GTR, complications, and functional outcomes. A multidisciplinary approach involving a skull base team is crucial for optimizing patient outcomes.
蝶骨-眶脑膜瘤(SOMs)是起源于蝶骨和眶部结构周围脑膜的罕见肿瘤。手术切除是SOMs的主要治疗方法。几十年来已描述了多种手术入路,包括显微手术经颅入路(MTAs)、内镜鼻内入路(EEAs)、内镜经眶入路(ETOAs)以及联合入路,手术入路的选择仍是一个有争议的话题。
本系统评价和荟萃分析旨在比较用于治疗SOMs的不同手术入路的临床和手术结果,讨论手术技术、结果以及影响手术决策的因素。
对PubMed、Ovid MEDLINE和Ovid EMBASE数据库进行全面文献检索,以查找截至2023年发表的关于手术治疗SOMs作用的文章。根据系统评价和荟萃分析的首选报告项目指南进行系统评价。进行荟萃分析以估计合并事件发生率并评估异质性。采用固定效应和随机效应模型评估症状表现、结果和并发症的95%置信区间(CIs)。
系统评价和荟萃分析共纳入59项研究,涉及1903例患者。大体全切除(GTR)率范围为:ETOAs为23.5%,MTAs为59.8%。术后总体复发率为20.7%。5年和10年的无进展生存率(PFS)分别为75.5%和49.1%。视力改善率和眼球突出改善率分别为57.5%和79.3%。20.6%的病例观察到术后颅神经(CN)局灶性缺损。总体脑脊液(CSF)漏率为3.9%,13.9%的病例发生其他并发症。MTAs的GTR率最高(59.8%,95%CI = 49.5 - 70.2%;P = 0.001),但与CN缺损增加相关(21.0%,95%CI = 14.5 - 27.6%)。ETOAs的GTR率最低(23.5%,95%CI = 0.0 - 52.5%;P = 0.001),而ETOA与EEA联合入路的CSF漏率最高(20.3%,95%CI = 0.0 - 46.7%;P = 0.551)。ETOAs与更好的眼球突出改善相关(79.4%,95%CI = 57.3 - 100%;P = 0.002),而解剖学I级病变与更好的视力(71.5%,95%CI = 63.7 - 79.4;P = 0.003)和眼球突出(60.1%,95%CI = 38.0 - 82.2;P = 0.001)恢复相关。不同手术入路的PFS率未发现显著差异。
SOMs的手术治疗旨在保留视觉功能并改善眼球突出。不同的手术入路在GTR率、并发症和功能结果方面有所不同。涉及颅底团队的多学科方法对于优化患者结局至关重要。